Biofina Diagnostics S.L will be attending the 111th American Urological Association’s Annual Meeting to be held in San Diego, California, from the 6th until the 10th of May.
Dr. Mengual will present a poster titled “Prospective, blinded, international and multicenter validation of a gene expression test for the non-invasive diagnosis of bladder cancer”. This poster includes performance results of a bladder cancer diagnostic kit tested in a prospective validation study performed in 5 European centers (N=525), as well as the results from a reproducibility study performed in an Asian population (N=69) in collaboration with the Fudan University Shanghai Cancer Center and the Institut Mérieux Laboratory. Performance is proved to be comparable to that achieved with the current invasive diagnostic method (cystoscopy and cytology). The use of spontaneous urine samples processed and a simple, objective and well-established technology like RT-qPCR turns the test into a non invasive alternative tool to the current gold-standard.
The poster will be on display in the Science and Technology Hall starting Saturday, May 7th at 10:30 am until Tuesday, May 10th at 1:00 pm to allow conference attendees an opportunity to view it throughout the meeting. In addition, interested viewers are invited to the Meet the Author event during the Saturday Afternoon Social (May 7, 4:00 – 5:30 pm) and speak informally with Dr. Mengual.
Biofina Diagnostics S.L. (www.finabiotech.es) is a new corporate vehicle incorporated to further develop and take UROBEST to the market, a bladder cancer non-invasive diagnostic test based on RT-qPCR technology. The company holds the exclusive exploitation and commercialization rights on Fina Biotech´s patents (www.finabiotech.es) protecting the diagnostic method. UROBEST has already been validated in clinical studies in more than 500 patients and has proven to have better sensitivity and specificity than competitive products (10-gene signature results: SN=80% and SP=94%). Biofina Diagnostics is currently exploring partnering opportunities that support the introduction of the test into the market both in Europe and the United States. UROBEST® is a registered trademark in the Spanish Patent and Trademark Office (OEPM).
